OBIO Form 4: Andrew Taylor Receives 80,000 RSUs with 24-36 Month Vesting

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. reported an award of 80,000 restricted stock units (RSUs) to reporting person Taylor Andrew Lawrence, identified as Chief Financial Officer, with an earliest transaction date of 08/07/2025. Each RSU represents a contingent right to one share of common stock and the reported acquisition was recorded at a price of $0 per RSU.

The RSUs vest in three tranches subject to the reporting person’s continuous service: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months after the grant date. After the award the reporting person beneficially owns 480,788 shares, reported as direct ownership. The Form 4 is signed by Andrew Taylor on 08/08/2025.

Insights

Financial Analyst

TL;DR: A routine executive equity award: 80,000 RSUs to the CFO increases direct holdings to 480,788; vesting is time-based over three years.

The filing documents an RSU grant to Taylor Andrew Lawrence, the Chief Financial Officer, dated 08/07/2025, recorded as an acquisition at $0 per unit. The award totals 80,000 RSUs, each representing one share, and is reported as direct ownership. The post-transaction beneficial holding is 480,788 shares. The RSUs vest in three tranches at 24, 30 and 36 months, each tranche contingent on continuous service. From a financial perspective this is a compensation-related equity grant with explicit vesting terms and no derivative transactions reported.

Corporate Governance Expert

TL;DR: Grant uses a staggered, service-contingent vesting schedule; the Form 4 discloses the award and resulting direct ownership precisely.

The Form 4 clearly states the nature of the award: 80,000 restricted stock units, each convertible into one share upon vesting. Vesting is specified as 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months post-grant, and is conditioned on continuous service. The filing reports direct beneficial ownership of 480,788 shares after the award and contains no entries in the derivatives table. The form is executed on 08/08/2025 by the reporting person. The disclosure meets standard Form 4 requirements for an equity compensation grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Andrew Lawrence

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	08/07/2025		A		80,000(1)	A	$0	480,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after the Grant Date, (ii) 33.33% of the shares will vest 30 months after the Grant Date, and (iii) 33.34% of the shares will vest 36 months after the Grant Date, subject to the Reporting Person's continuous service through such dates.

	/s/ Andrew Taylor	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What RSU award did Orchestra BioMed (OBIO) report on 08/07/2025?

The filing reports an award of 80,000 restricted stock units (RSUs) to reporting person Taylor Andrew Lawrence on 08/07/2025.

How do the 80,000 RSUs vest?

The RSUs vest in three tranches: 33.33% at 24 months, 33.33% at 30 months and 33.34% at 36 months after the grant date, subject to continuous service.

What price and ownership form were reported for the transaction?

The acquisition was reported at a price of $0 per RSU and the resulting holdings are reported as direct ownership.

How many shares does the reporting person own after the transaction?

Following the reported transaction the reporting person beneficially owns 480,788 shares (direct).

Who signed the Form 4 and when was it signed?

The Form 4 is signed by /s/ Andrew Taylor with a signature date of 08/08/2025.

Does the filing report any derivative securities or option exercises?

No. Table II for derivative securities contains no reported entries in this filing.